After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

Messenger RNA (mRNA) vaccines against COVID‐19 are the first authorized biological
preparations developed using this platform. During the pandemic, their administration has …

Beginning in 2009, studies of the humoral responses of HIV‐positive individuals have led to
the identification of scores, if not hundreds, of antibodies that are both broadly reactive and …

Broadly neutralizing antibodies (bnAbs) are thought to be a critical component of a
protective HIV vaccine. However, designing vaccines immunogens able to elicit bnAbs has …

The HIV-1 envelope glycoprotein trimer is covered by an array of N-linked glycans that
shield it from immune surveillance. The high density of glycans on the trimer surface …

A preventive HIV-1 vaccine should induce HIV-1–specific broadly neutralizing antibodies
(bnAbs). However, bnAbs generally require high levels of somatic hypermutation (SHM) to …

Induction of HIV‐1 broadly neutralizing antibodies (bnAbs) to date has only been observed
in the setting of HIV‐1 infection, and then only years after HIV transmission. Thus, the …

Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global
viruses, are a major focus of HIV vaccine design, with data from animal studies confirming …

Progress in the last year has provided support for the use of rationally stabilized whole HIV-1
trimers as immunogens for eliciting antibodies to multiple epitopes. Furthermore, the …

Since their discovery, antibodies capable of broad neutralisation have been at the forefront
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …